GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Senestech SNES · USD

Health Care · US listing · 🇺🇸 United States

Compare

1.14

+2.70%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Senestech

From its filings with the US Securities and Exchange Commission

SEC filings

Senestech is based in Phoenix, Arizona and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker SNES. The SEC classifies its business as agricultural chemicals. In the fiscal year to 31 December 2025, it reported revenue of $2.2m and a net loss of $6.4m. At that date it held total assets of $12.8m and shareholders' equity of $9.6m.

In its own words

We have developed and are commercializing products for managing animal pest populations through fertility control and population management strategies. Our current products focus on rat and mouse populations, and are known as: ContraPest, Evolve Rat, and Evolve Mouse.

As far back as we can trace, rodents have been foes to mankind. Today, they remain one of the most resilient and economically destructive vertebrate pests on the planet. Rodents threaten human and animal health, food security, and infrastructure worldwide, and humanity has spent centuries attempting to mitigate the problems associated with their proliferation. Rodents pose threats to human and animal health, food security and infrastructure around the world, and humanity has spent centuries trying to mitigate the problems associated with these pests. Rodents are known to be reservoir hosts for at least 60 zoonotic diseases and the potential transmission of these diseases creates a global risk to public health and safety, as well as agriculture, affecting crops, livestock, stored grain, and farm workers. Diseases such as leptospirosis and salmonellosis directly impact reproductive efficiency in livestock, contaminate feed supplies, and increase liability exposure for agricultural operators.

Quoted from its 10-K, filed 13 Mar 2026. Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
8 Dec 2016
Employees
23
Head office
777 W. PINNACLE PEAK ROAD, PHOENIX, AZ, 85027
Incorporated in
DE
Classification
Agricultural Chemicals
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Dr. Jamie BechtelIndependent Chairman of the Board$107,276
  • Mr. Joel FruendtPresident, Chief Executive Officer, Director, since 2022$575,809
  • Mr. Thomas ChestermanChief Financial Officer, Executive Vice President, Treasurer, Secretary$364,178
  • Ms. Lynn GrahamIndependent Director
  • Mr. Phil GrandinettiIndependent Director$54,776
  • Mr. Jake LeachIndependent Director$64,776
  • Mr. Joshua MossIndependent Director
  • Mr. Matthew SzotIndependent Director$92,276

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • SenesTech Inc develops ContraPest for rat fertility control in the pest management industry.
  • SenesTech's pipeline includes feral animal fertility control for dogs and hogs in population management.
  • SenesTech's non-surgical spay and neutering targets companion animals in the health sector.

Weaknesses

  • SenesTech has only 23 employees in the Health Care sector.
  • SenesTech's IPO was on 8 December 2016 with limited market presence.
  • SenesTech's product ContraPest is limited to rat fertility control in pest management.

Opportunities

  • SenesTech's feral animal fertility control targets feral dogs and hogs in population management.
  • SenesTech's non-surgical spay and neutering targets companion dogs and cats in health care.
  • SenesTech's boar taint application targets boars in food production and safety.

Threats

  • SenesTech's pipeline includes animal cancer treatment which is a high-risk segment.
  • SenesTech's product ContraPest faces competition in the pest control industry.
  • SenesTech's business is limited to animal fertility control in the Health Care sector.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.